Yungshin Acquired 100% of Shares of Zoetis Biotech Manufacturing Limited to Improve Capacity for Animal Healthcare Products

After the board of directors approved on January 14, 2016, Yungshin Pharm Ind. Co. LTD (Yungshin), a subsidiary of Yungshin Global Holding (3705) signed the contract with Zoetis Biotech Manufacturing Limited to acquire 100% of its shares. After settlement, Zoetis Biotech Manufacturing Limited will become a subsidiary of Yungshin. 

Founded in the U.S. in 2012, Zoetis formerly was the animal business department of Pfizer, Inc. specializing in manufacturing and selling vaccines, chemicals, and feed additives. In 2015, the turnover of Zoetis Biotech Manufacturing Limited, a subsidiary of Zoetis in Taiwan, is NT$600 million. 

The settlement of this investment will result in more than 180 permit licenses to sell animal products domestically and 40 permit licenses to export to China, Southeast Asia, and Central and South America. Well-known brands, such as Aureo, Acidofac, Prebiotics, and Pulmoeasy, are authorized to Yungshin to sell in Taiwan. The production plan transferred to Yungshin will significantly improve Yungshin’s capacity of animal products in global markets.